keyword
MENU ▼
Read by QxMD icon Read
search

Vedolizumab

keyword
https://www.readbyqxmd.com/read/29471605/-emerging-therapies-what-are-promising-in-the-near-future
#1
REVIEW
Geom Seog Seo, Sung Hee Lee
The treatment of inflammatory bowel disease has evolved with the development of anti-TNF agents. In spite of long-term effectiveness, many patients do not respond or no longer responds to these drugs. Therefore, the development of new drugs that act on different inflammatory pathways has become necessary. Vedolizumab, a gut-specific biological agent, inhibits interaction α4β7 integrin with mucosal addressin cell adhesion molecule-1 without inhibiting systemic immune responses. Long-term vedolizumab therapy in patients with Crohn's disease and ulcerative colitis was safe and effective...
February 25, 2018: Korean Journal of Gastroenterology, Taehan Sohwagi Hakhoe Chi
https://www.readbyqxmd.com/read/29471381/efficacy-of-vedolizumab-in-fistulising-crohn-s-disease-exploratory-analyses-of-data-from-gemini-2
#2
Brian G Feagan, David Schwartz, Silvio Danese, David T Rubin, Trevor W Lissoos, Jing Xu, Karen Lasch
Background and Aims: Medical management of fistulising Crohn's disease (CD) is constrained by the limited number of available therapies. We evaluated the efficacy of vedolizumab, a gut-selective α4β7 integrin antagonist approved for treating moderately to severely active CD, in a subpopulation of patients with fistulising CD who participated in the GEMINI 2 trial (NCT00783692). Methods: Exploratory analyses of data from the GEMINI 2 trial were conducted in 461 responders to 6-week vedolizumab induction therapy who received maintenance placebo (VDZ/PBO, N=153) or vedolizumab (VDZ/VDZ, N=308)...
February 17, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29462391/combination-immunosuppression-in-ibd
#3
Steven Bots, Krisztina Gecse, Murray Barclay, Geert D'Haens
Whether to use biologic treatment for inflammatory bowel disease as monotherapy or in combination with immunosuppressives has been a matter of debate in the last 2 decades. Combination therapy was not superior in any of the registration trials for Crohn's disease and ulcerative colitis for TNF antagonists, vedolizumab, or ustekinumab. It needs to be mentioned, though, that none of these trials were powered to detect such differences, and that many patients entered the trial after having failed conventional immunosuppressives...
February 15, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29462385/the-use-of-vedolizumab-in-preventing-postoperative-recurrence-of-crohn-s-disease
#4
Akihiro Yamada, Yuga Komaki, Nayan Patel, Fukiko Komaki, Joel Pekow, Sushila Dalal, Russell D Cohen, Lisa Cannon, Konstantin Umanskiy, Radhika Smith, Roger Hurst, Neil Hyman, David T Rubin, Atsushi Sakuraba
Background: Clinical and endoscopic recurrence are common after surgery in Crohn's disease (CD). Vedolizumab has been increasingly used to treat CD, however, its effectiveness in preventing postoperative recurrence remains unknown. We aimed to investigate the use of vedolizumab in the postoperative setting and compare the risk of recurrence between patients receiving vedolizumab and anti-tumor necrosis factor (TNF)-α agents. Methods: Medical records of CD patients who underwent surgery between April 2014 and June 2016 were reviewed...
February 15, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29446098/safety-efficacy-and-pharmacokinetics-of-vedolizumab-in-patients-with-simultaneous-exposure-to-an-anti-tumour-necrosis-factor
#5
S Ben-Horin, B Ungar, U Kopylov, A Lahat, M Yavzori, E Fudim, O Picard, Y Peled, R Eliakim, E Del Tedesco, S Paul, X Roblin
BACKGROUND: Data on combination-biologic treatment in (IBD) are still scant. AIM: To explore outcomes of patients co-exposed to anti-TNF and vedolizumab. METHODS: Patients starting vedolizumab having measurable anti-TNF levels after recently stopping adalimumab/infliximab ('VDZ-aTNF' group), were compared with control vedolizumab patients in a retrospective 1:2 matched case-control study. RESULTS: Seventy-five patients were included (25 VDZ-aTNF, 50 VDZ)...
February 15, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29430672/review-article-predictors-of-response-to-vedolizumab-and-ustekinumab-in-inflammatory-bowel-disease
#6
REVIEW
A Barré, J-F Colombel, R Ungaro
BACKGROUND: Increased knowledge of pathways involved in the pathogenesis of IBD has led to the development of new treatment options for Crohn's disease (CD) and ulcerative colitis (UC). Two new biological agents have been recently approved for IBD: vedolizumab and ustekinumab. They have different therapeutic targets (α4 β7 integrin for vedolizumab and interleukin-12/23 pathways for ustekinumab) than the primary biological class, anti-tumour necrosis factor alpha (anti-TNF) agents. As the armamentarium for IBD increases in coming years, it will become important to understand factors associated with response in order to best position and personalise therapy...
February 12, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29427804/escmid-study-group-for-infections-in-compromised-hosts-esgich-consensus-document-on-the-safety-of-targeted-and-biological-therapies-an-infectious-diseases-perspective-immune-checkpoint-inhibitors-cell-adhesion-inhibitors-sphingosine-1-phosphate-receptor-modulators
#7
REVIEW
Gil Redelman-Sidi, Olivier Michielin, Carlos Cervera, Camillo Ribi, José María Aguado, Mario Fernández-Ruiz, Oriol Manuel
BACKGROUND: The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. AIMS: To review, from an Infectious Diseases perspective, the safety profile of immune checkpoint inhibitors, LFA-3-targeted agents, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors and to suggest preventive recommendations. SOURCES: Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family...
February 7, 2018: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/29411220/novel-therapies-and-treatment-strategies-for-patients-with-inflammatory-bowel-disease
#8
REVIEW
Marjolijn Duijvestein, Robert Battat, Niels Vande Casteele, Geert R D'Haens, William J Sandborn, Reena Khanna, Vipul Jairath, Brian G Feagan
PURPOSE OF REVIEW: This article reviews current treatment options and strategies and provides an update on the status of drug development programs of new therapeutic agents for inflammatory bowel diseases (IBD). RECENT FINDINGS: In the past two decades, tumor necrosis factor antagonist therapy has given clinicians better treatment options. However, not all patients respond to induction therapy with these agents, and of those initially responding, up to 40% ultimately lose response due to suboptimal drug exposure (e...
February 6, 2018: Current Treatment Options in Gastroenterology
https://www.readbyqxmd.com/read/29406811/vedolizumab-for-the-treatment-of-crohn-s-disease
#9
Marjorie Argollo, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese
Crohn's disease (CD) is an immune-mediated condition characterized by inflammation of the gut tissue, associated with progressive damage of the affected intestinal tract and possible complications. A treat-to-target approach is strongly advocated, consisting of early and aggressive inflammatory control. However, a great proportion of affected subjects lack response or are intolerant to conventional therapy. Even though the first-line biologic therapy targeting tumor necrosis factor-alfa (TNF-α) is associated with improvement of inflammation in some patients, others do not respond at first or lose response over time...
February 6, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29385425/corrigendum-exposure-efficacy-relationships-for-vedolizumab-induction-therapy-in-patients-with-ulcerative-colitis-or-crohn-s-disease
#10
Maria Rosario, Jonathan L French, Nathanael L Dirks, Serap Sankoh, Asit Parikh, Huyuan Yang, Silvio Danese, Jean-Frédéric Colombel, Michael Smyth, William J Sandborn, Brian G Feagan, Walter Reinisch, Bruce E Sands, Miguel Sans, Irving Fox
No abstract text is available yet for this article.
January 29, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29384209/early-vedolizumab-trough-levels-predict-mucosal-healing-in-inflammatory-bowel-disease-a-multicentre-prospective-observational-study
#11
W Yacoub, N Williet, L Pouillon, T Di-Bernado, M De Carvalho Bittencourt, S Nancey, A Lopez, S Paul, C Zallot, X Roblin, L Peyrin-Biroulet
BACKGROUND: The correlation between vedolizumab trough levels during induction therapy and mucosal healing remains unknown. AIM: To compare early vedolizumab trough levels in patients with and without mucosal healing within the first year after treatment initiation. METHODS: We prospectively collected vedolizumab trough levels in all inflammatory bowel disease patients at weeks 2, 6 and 14 of vedolizumab treatment in three French referral centres between 1 June 2014 and 31 March 2017...
January 31, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29383030/immunogenicity-of-biologics-in-inflammatory-bowel-disease
#12
Séverine Vermeire, Ann Gils, Paola Accossato, Sadiq Lula, Amy Marren
Crohn's disease and ulcerative colitis are chronic inflammatory disorders of the gastrointestinal tract. Treatment options include biologic therapies; however, a proportion of patients lose response to biologics, partly due to the formation of anti-drug antibodies (ADAbs). Concomitant immunosuppressive agents reduce the development of ADAbs. This review article aims to assess the immunogenicity of biologic therapies and their clinical implications. A comprehensive literature search was conducted for articles published January 2009 to August 2015 reporting immunogenicity to adalimumab (ADM), certolizumab pegol (CZP), golimumab, infliximab (IFX), ustekinumab, and vedolizumab in inflammatory bowel disease (IBD)...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/29383027/inflammatory-bowel-disease-towards-a-personalized-medicine
#13
REVIEW
Mathurin Flamant, Xavier Roblin
The management of inflammatory bowel disease (IBD) has been transformed over the last two decades by the arrival of tumor necrosis factor (TNF) antagonist agents. Recently, alternative drugs have been approved, directed at leukocyte-trafficking molecules (vedolizumab) or other inflammatory cytokines (ustekinumab). New therapeutics are currently being developed in IBD and represent promising targets as they involve other mechanisms of action (JAK molecules, Smad 7 antisense oligonucleotide etc.). Beyond TNF antagonist agents, these alternative drugs are needed for early-stage treatment of patients with aggressive IBD or when the disease is resistant to conventional therapy...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/29377235/vedolizumab-in-patients-with-concurrent-primary-sclerosing-cholangitis-and-inflammatory-bowel-disease-does-not-improve-liver-biochemistry-but-is-safe-and-effective-for-the-bowel-disease
#14
B Christensen, D Micic, P R Gibson, A Yarur, E Bellaguarda, P Corsello, J N Gaetano, J Kinnucan, V L Rao, S Reddy, S Singh, J Pekow, D T Rubin
BACKGROUND: Blocking of lymphocyte trafficking to bile ducts is a potential mechanism to alter the disease course of patients with primary sclerosing cholangitis (PSC). AIM: To describe the effect of the α4 β7 integrin antibody, vedolizumab, on liver biochemistry and disease activity in patients with PSC and inflammatory bowel disease (IBD). METHODS: This is a retrospective multi-centre study of adult patients with a diagnosis of both IBD and PSC...
January 29, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29374617/efficacy-of-medical-therapies-for-fistulizing-crohn-s-disease-systematic-review-and-meta-analysis
#15
REVIEW
Matthew J Lee, Claire E Parker, Sarah R Taylor, Leonardo Guizzetti, Brian G Feagan, Alan J Lobo, Vipul Jairath
BACKGROUND & AIMS: Fistulas are debilitating complications of Crohn's disease (CD) that affect up to 50% of patients. We conducted a systematic review and meta-analysis of randomized controlled trials to assess the efficacy of treatments for fistulizing CD. METHODS: We searched publication databases from inception through December 13, 2016 for trials comparing the efficacy of a therapeutic agent (single or combination) with placebo or another active therapy in adult patients with any form of fistulizing CD...
January 25, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29372476/identification-of-candidate-biomarkers-associated-with-response-to-vedolizumab-in-inflammatory-bowel-disease
#16
Elisa K Boden, Donna M Shows, Michael V Chiorean, James D Lord
BACKGROUND/AIMS: Vedolizumab is an anti-α4β7 monoclonal antibody approved for the treatment of inflammatory bowel disease (IBD). This exploratory study aimed to identify biomarkers associated with vedolizumab response. METHODS: Twenty-six IBD patients (15 with Crohn's, 11 with ulcerative or indeterminate colitis) initiating vedolizumab at a single center between 2014 and 2016 underwent sampling of serum and peripheral blood mononuclear cells (PBMCs) before and during vedolizumab therapy...
January 25, 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29370898/postoperative-complications-of-pediatric-patients-with-inflammatory-bowel-disease-treated-with-vedolizumab
#17
Lori A Zimmerman, Jill M Zalieckas, Robert C Shamberger, Athos Bousvaros
BACKGROUND: Vedolizumab is a biologic, which inhibits leukocyte adhesion in the gut and is used to treat ulcerative colitis (UC) and Crohn's disease (CD). Little is known of the surgical outcomes in patients treated with vedolizumab. We reviewed the postoperative complications in a cohort of pediatric UC and CD patients treated with vedolizumab. METHODS: We identified pediatric UC and CD patients treated with vedolizumab at our institution from 2014 to 2016. We compared postoperative outcomes in the vedolizumab exposed group to a cohort of vedolizumab naïve patients who required diverting ileostomy...
December 16, 2017: Journal of Pediatric Surgery
https://www.readbyqxmd.com/read/29370397/primary-non-response-to-tumor-necrosis-factor-antagonists-is-associated-with-inferior-response-to-second-line-biologics-in-patients-with-inflammatory-bowel-diseases-a-systematic-review-and-meta-analysis
#18
Siddharth Singh, John George, Brigid S Boland, Niels Vande Casteele, William J Sandborn
Background and Aims: We sought to analyze whether response to second-line biologic varies depending on reason for discontinuation of primary anti-TNF agent (primary non-response [PNR], secondary loss of response [LOR] after initial response, or intolerance), through a systematic review and meta-analysis. Methods: Through a systematic search through May 31, 2017, we identified 8 randomized controlled trials (RCTs) of biologics in patients with IBD with prior exposure to anti-TNF agents, that stratified response to second-line therapy by reason for discontinuing primary anti-TNF therapy (PNR vs...
January 23, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29361100/assessing-the-optimal-position-for-vedolizumab-in-the-treatment-of-ulcerative-colitis-a-simulation-model
#19
Frank I Scott, Yash Shah, Karen Lasch, Michelle Luo, James D Lewis
Background: Vedolizumab, an α4β7 integrin monoclonal antibody inhibiting gut lymphocyte trafficking, is an effective treatment for ulcerative colitis (UC). We evaluated the optimal position of vedolizumab in the UC treatment paradigm. Methods: Using Markov modeling, we assessed multiple algorithms for the treatment of UC. The base case was a 35-year-old male with steroid-dependent moderately to severely active UC without previous immunomodulator or biologic use...
January 18, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29359519/predicting-corticosteroid-free-endoscopic-remission-with-vedolizumab-in-ulcerative-colitis
#20
A K Waljee, B Liu, K Sauder, J Zhu, S M Govani, R W Stidham, P D R Higgins
BACKGROUND: Vedolizumab is an effective therapy for ulcerative colitis (UC), but costly and slow to work. New clinical responses occur after 30 weeks of therapy. AIMS: To enable physicians, patients, and insurers to predict whether a patient with UC will respond to vedolizumab at an early time point after starting therapy. METHODS: The clinical study data request website provided the phase 3 clinical trial data for vedolizumab. Random forest models were trained on 70% and tested on 30% of the data to predict corticosteroid-free endoscopic remission at week 52...
January 22, 2018: Alimentary Pharmacology & Therapeutics
keyword
keyword
1883
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"